Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A7 | Q99884 | 1/20 | 0.65 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | NAMPT | P43490 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4425017 | 0.91 | SLC6A7 (0.56) | SLC6A7ALDH1A1HPGD | |
| SCHEMBL4415437 | 0.90 | SLC6A7 (0.64) | SLC6A7NAMPT | |
| SCHEMBL4319854 | 0.89 | SLC6A7 (0.62) | SLC6A7NAMPT | |
| SCHEMBL4321986 | 0.87 | MEN1 (0.69) | SLC6A7MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL11080932 | 0.86 | SLC6A7 (0.85) | SLC6A7MEN1KMT2AALDH1A1NAMPT | |
| SCHEMBL4415931 | 0.86 | SLC6A7 (0.61) | SLC6A7ALDH1A1NAMPT | |
| SCHEMBL4419055 | 0.85 | SLC6A7 (0.58) | SLC6A7 | |
| SCHEMBL4428085 | 0.85 | ALDH1A1 (0.62) | MEN1KMT2AALDH1A1HPGD | |
| SCHEMBL4415241 | 0.83 | HPGD (0.64) | MEN1KMT2AHPGD | |
| SCHEMBL4419169 | 0.81 | TSHR (0.63) | ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1583742-B1 | CB 1 RECEPTOUR INVERSE AGONISTS | HOFFMANN LA ROCHE (CH) | 2009-12-02 | — | — | EP | claimed |
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | WYETH (US) | 2009-12-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325964-A1 | Piperazine Metabotropic Glutamate Receptor 5 (MGLUR5) Negative Allosteric Modulators For Anxiety/Depression | GRM5, GRIK5, GRM1 | SLC6A7 234/4885MEN1 4398/4885KMT2A 887/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.